首页 › 期刊 › 医学 › Oncology Research and Treatment
Oncology Research and Treatment
出版商:S. Karger AG · ISSN:2296-5270, 2296-5262 · 国家/地区:CH · 类型:journal · 官网:http://www.karger.com?issn=2296-5262
研究主题:Human auditory perception and evaluation · Diverse Scientific and Economic Studies · Educational Robotics and Engineering · Lung Cancer Treatments and Mutations · Cancer Treatment and Pharmacology
数据覆盖:9 个公开学术数据源交叉核验(crossref、fqb、jcr、openalex、scimago、wikidata、xr、cwts、jufo)。
数据来源与实体核验
期刊官网 · OpenAlex 期刊实体 · Wikidata 期刊实体
核心指标
- 影响因子(JCR 2025):1.400
- JCR 分区:Q4(ONCOLOGY)
- 中科院分区(2025):医学 4区,大类排名 3290/5603;小类:ONCOLOGY 肿瘤学 4区,排名 219/318
- 新锐分区(2026):医学 4区
- SJR:0.482(Q3),2025 年,Switzerland
- CWTS 2025:SNIP 0.449 · IPP 1.245 · 自引率 1.5%
- JUFO 出版渠道等级:芬兰 1 · 挪威 1
- h-index:63
- i10 指数:870
- 近两年篇均被引:1.02
- 载文量 3709 · 总被引 29664
- Crossref DOI 总量:3687,近期 263
逐年趋势
- 近年影响因子:2020 2.83 → 2021 2.84 → 2022 2.4 → 2023 2 → 2024 1.6
- 近年 SJR:2021 0.624(Q2) → 2022 0.495(Q3) → 2023 0.521(Q3) → 2024 0.589(Q2) → 2025 0.482(Q3)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- MMWR Surveillance Summaries — IF 96.9 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《Oncology Research and Treatment》的影响因子是多少?
根据 JCR 2025 年数据,《Oncology Research and Treatment》的最新影响因子(IF)为 1.400。
《Oncology Research and Treatment》是几区期刊?
《Oncology Research and Treatment》中科院分区(2025年版)为医学4区,JCR 分区为 Q4。
本刊近期代表论文
- Clinicopathological Features, Prognostic Factors, Survival Trends, and Treatment of Malignant Ovarian Germ Cell Tumors: A SEER Database Analysis (2021 · 被引 29)
- [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors (2021 · 被引 23)
- Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis (2020 · 被引 11)
- Platelet-Lymphocyte Ratio as a Predictor of Prognosis in Head and Neck Cancer: A Systematic Review and Meta-Analysis (2019 · 被引 50)
- Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma (2019 · 被引 41)
- Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia (2018 · 被引 86)